XML 18 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Balance Sheets - USD ($)
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 19,136,472 $ 57,632,693
Short-term investments 85,629,412 105,357,277
Accounts receivable 15,821,511 7,299,612
Accounts receivable from affiliated entity 748,355 33,447
Prepaid expenses and other current assets 1,749,059 917,257
Prepaid expenses and other current assets from affiliated entity 1,512,424 610,652
Total current assets 124,597,233 171,850,938
Fixed assets, net 9,025,446 7,306,695
Investment in affiliated entity - GeneOne 16,052,065 14,941,277
Investment in affiliated entity - PLS 3,777,510 5,045,915
Intangible assets, net 7,628,394 3,905,860
Goodwill 10,513,371 10,113,371
Common stock warrants 0 5,970
Other assets 2,113,147 670,833
Total assets 173,707,166 213,840,859
Current liabilities:    
Accounts payable and accrued expenses 19,597,787 13,064,899
Accounts payable and accrued expenses due to affiliated entity 1,072,579 165,047
Accrued clinical trial expenses 6,368,389 2,600,483
Common stock warrants 1,167,614 1,301,138
Deferred revenue 14,762,720 13,449,768
Deferred revenue from affiliated entity 407,292 504,442
Deferred rent 446,646 380,629
Total current liabilities 43,823,027 31,466,406
Deferred revenue, net of current portion 317,808 103,074
Deferred revenue from affiliated entity, net of current portion 86,694 677,371
Deferred rent, net of current portion 5,926,424 5,485,313
Deferred tax liabilities 174,793 175,642
Total liabilities 50,328,746 37,907,806
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December 31, 2016 and December 31, 2015 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2016 and December 31, 2015, issued and outstanding: 74,062,370 at December 31, 2016 and 72,217,965 at December 31, 2015 74,062 72,218
Additional paid-in capital 556,718,356 534,004,564
Accumulated deficit (434,838,235) (361,097,896)
Accumulated other comprehensive income 1,327,968 2,708,339
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 123,282,151 175,687,225
Non-controlling interest 96,269 245,828
Total stockholders' equity 123,378,420 175,933,053
Total liabilities and stockholders’ equity $ 173,707,166 $ 213,840,859